Clinical trial
Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
NCT00431210 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00431210 |
|---|---|
| Title | Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma |
| Official title | A Pilot Feasibility Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Nasopharyngeal Carcinoma |
| Intervention type | Biological |
| Interventions | Epstein-Barr virus-specific adoptive T-cells immunotherapy |
| Enrollment | 28 |
| Start date | Feb 1, 2007 |
| Primary completion | Jun 30, 2015 |
| Completion | Jan 26, 2016 |
| First posted | Feb 5, 2007 |
| Last update posted | Apr 18, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: